A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

NCT06508983 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: SG301 Injection
DRUG: SG301 placebo
DRUG: pomalidomide
DRUG: dexamethasone

Sponsor

Hangzhou Sumgen Biotech Co., Ltd.